PDCD1 and myelodysplastic syndrome: Other relevant PD-1 inhibitors include nivolumab and pembrolizumab that are still being evaluated in phase 1b and 2 trials (NCT01953692, NCT02397720) respectively in MDS/AML patients after HMA failure (242, 243).